Cipla's Goa facility gets VAI status after US FDA inspection

Business To Business, New Delhi, 11^th June, 2026:    Cipla on Thursday announced that its manufacturing facility in Goa has been classified as Voluntary Action Indicated (VAI) by the United States Food and Drug Administration (USFDA).
Inspection Details
The USFDA conducted an inspection of Cipla's Goa facility in April 2026. Following the inspection, the regulator communicated on June 10, 2026, that the site had been classified as VAI, the company said in a regulatory filing.
What Does VAI Mean?
A Voluntary Action Indicated (VAI) classification means:

• The USFDA identified certain objectionable conditions or observations during the inspection.
• The observations do not warrant official regulatory enforcement action at this stage.
• The company is expected to address the observations voluntarily.

1. No Action Indicated (NAI) – No significant objectionable conditions found.
2. Voluntary Action Indicated (VAI) – Observations found, but voluntary corrective action is considered sufficient.
3. Official Action Indicated (OAI) – Significant deficiencies that may lead to regulatory action.

• Review the observations made by inspectors.
• Implement corrective and preventive actions where required.
• Maintain compliance with current good manufacturing practices (cGMP).